|
|
|
|
|
|
INSTITUTE OF LIFE SCIENCES
No. 129 - September 2024
|
|
|
|
|
|
|
|
The antiviral drug Lenacapavir, from the pharmaceutical company Gilead, has managed to prevent 100% of AIDS infections in women with a dose of two injections per year. The PURPOSE 1 study was conducted out only in women because they represent a significant proportion of new HIV infections in many regions of the world, especially in sub-Saharan Africa. The results of …
|
|
|
|
|
|
An article published in Medscape discusses the policies recently adopted in different European countries regarding the management of gender dysphoria in minors. These policies are mostly being redirected towards a more psychologically supportive approach and warn of the dangers of using hormone blockers at an early age. Medscape is one of the leading online reference sites for doctors and healthcare …
|
|
|
|
|
|
A study entitled "Recovery Potential in Patients who Died after Withdrawal of Life-sustaining Treatment” has recently been published in the Journal of Trauma (1). In the article, the authors analyzed the ability of certain clinical scales to predict the survival and functional recovery of patients with severe head trauma. The most remarkable conclusion of the study, which was conducted in …
|
|
|
|
|
|
A recent study analyzes the surplus of cryopreserved human embryos surplus from in vitro fertilization techniques stored in the United Kingdom. According to this research, their number is the highest since records began in 1991 by the UK Human Fertilisation and Embryology Authority (HFEA). The paper presents a quantitative analysis of the data from 1991 to 2019 provided by the …
|
|
|
|
|
|
|
|
More and more countries are rectifying their procedures for dealing with gender dysphoria when it comes to providing hormone blockers to people at an early age. Puberty blockers are used in minors with gender dysphoria to stop or delay the adolescent maturation process in order to reduce the sexual differentiation of this stage with a view to a later surgical …
|
|
|
|
|
|
|
|
|
Your email address is listed in our database in order to continue to send you information that we consider of interest. Nevertheless, in accordance with Spanish laws on data protection, particularly Law 34/2002 on Information Society Services and E-Commerce, you can unsubscribe from receiving these types of notifications at any time, and delete your data from our listing, through the following link: UNSUBSCRIBE. In accordance with current legislation on personal data protection, you can also exercise your rights of access, rectification, deletion, portability, limitation and opposition, as appropriate, by sending a written request, together with a photocopy of your identity document, to: UCV-LOPD Observatorio de Bioética, Plaza San Agustín, 3 Entlo. B Puerta C 46002 Valencia or, where necessary, to our Delegate in Data Protection dpd@ucv.es
|
|
|
|
|
|
|
|
|
|
Bioethics Observatory - Institute of Life Sciences - Catholic University of Valencia
|
|
|
|
|
